Analyzing Edwards Lifesciences (NYSE:EW) and Baird Medical Investment (NASDAQ:BDMD)

Baird Medical Investment (NASDAQ:BDMD) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Valuation and Earnings

This table compares Baird Medical Investment and Edwards Lifesciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	N/A	N/A	N/A	N/A	N/A
Edwards Lifesciences	$6.07 billion	7.74	$1.07 billion	$1.83	44.52

Edwards Lifesciences has higher revenue and earnings than Baird Medical Investment.

Institutional and Insider Ownership

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by company insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Baird Medical Investment and Edwards Lifesciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1	0	0	0	1.00
Edwards Lifesciences	0	9	16	3	2.79

Edwards Lifesciences has a consensus price target of $95.96, suggesting a potential upside of 17.79%. Given Edwards Lifesciences’ stronger consensus rating and higher probable upside, analysts clearly believe Edwards Lifesciences is more favorable than Baird Medical Investment.

Profitability

This table compares Baird Medical Investment and Edwards Lifesciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Edwards Lifesciences	17.69%	14.50%	11.21%

Volatility & Risk

Baird Medical Investment has a beta of -1.14, suggesting that its stock price is 214% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Baird Medical Investment on 10 of the 11 factors compared between the two stocks.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.